Aspira Pathlab & Diagnostics Ltd
BSE:540788
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| IN |
|
Aspira Pathlab & Diagnostics Ltd
BSE:540788
|
688.3m INR |
Loading...
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
23B USD |
Loading...
|
|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
21.3B USD |
Loading...
|
|
| CN |
|
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
|
56.1B CNY |
Loading...
|
|
| AU |
|
Sonic Healthcare Ltd
ASX:SHL
|
10.6B AUD |
Loading...
|
|
| SE |
|
Medicover AB
STO:MCOV B
|
30.6B SEK |
Loading...
|
|
| DE |
|
Synlab AG
XETRA:SYAB
|
2.4B EUR |
Loading...
|
|
| US |
|
Veracyte Inc
NASDAQ:VCYT
|
2.8B USD |
Loading...
|
|
| IN |
|
Dr. Lal PathLabs Ltd
NSE:LALPATHLAB
|
240.3B INR |
Loading...
|
|
| CN |
|
Dian Diagnostics Group Co Ltd
SZSE:300244
|
14.7B CNY |
Loading...
|
|
| CN |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SSE:603882
|
14.4B CNY |
Loading...
|
Market Distribution
| Min | -305 007.7% |
| 30th Percentile | 2.1% |
| Median | 5.8% |
| 70th Percentile | 11.6% |
| Max | 1 221 633.3% |
Other Profitability Ratios
Aspira Pathlab & Diagnostics Ltd
Glance View
Aspira Pathlab & Diagnostics Ltd. engages in the operation of diagnostic centers and laboratories. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2017-12-05. The principal activities of the Company consist of pathology investigation services, radiology investigation services and other related healthcare services at diagnostic centers in Mumbai. The firm carries out pathological investigations in various branches, including bio-chemistry, hematology, histopathology, microbiology, immuno-chemistry, immunology, virology, cytology, other pathological and radiological investigations. The firm's tests include COVID-19 tests, health packages and pathology tests. Its COVID-19 tests include Shanti Screening Test, COVID-19 Antibody Test, COVID-19 Surveillance Profile, COVID-19 RT-PCR Test, COVID-19 Detection Profile 1 and others.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Aspira Pathlab & Diagnostics Ltd is 13.2%, which is above its 3-year median of -2.6%.
Over the last 3 years, Aspira Pathlab & Diagnostics Ltd’s Net Margin has increased from 12.1% to 13.2%. During this period, it reached a low of -20.2% on Mar 31, 2024 and a high of 13.2% on Oct 30, 2025.
